tert-butyl 4-(2-chlorophenyl)piperazine-1-carboxylate | 1104513-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(2-chlorophenyl)piperazine-1-carboxylate
• CAS: 1104513-49-6
• 化学式: C₁₅H₂₁ClN₂O₂
• 分子量: 296.797
• InChiKey: KXZHQICGNSMOCT-UHFFFAOYSA-N

物化性质

• 沸点：
  397.1±37.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-chlorophenyl)piperazine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-(邻氯苯基)哌嗪盐酸盐
  参考文献：
  名称：

  [EN] REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  [FR] RÉGULATEUR CONTENANT UN DÉRIVÉ TRICYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 含三并环类衍生物调节剂、其制备方法和应用

  摘要：

  涉及含三并环类衍生物调节剂、其制备方法和应用。特别地，涉及通式(Ia)所示的化合物、其制备方法及含有该化合物的药物组合物，及其在制备预防和/或治疗与哺乳动物5-羟色胺和/或多巴胺和/或去甲肾上腺素神经递质传递相关的中枢神经系统疾病和/或外周疾病药物中的应用。

  公开号：

  WO2023011608A1
• 作为产物：
  描述：

  N-Boc-哌嗪 在 N-氯代丁二酰亚胺 、 cesium fluoride 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 tert-butyl 4-(2-chlorophenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Insertion of Arynes into N-Halo Bonds: A Direct Approach to o-Haloaminoarenes

  摘要：

  A new approach to access o-haloaminoarenes has been achieved by insertion of arynes into a nitrogen-halide bond (N-X). This transition-metal-free transformation displays a broad substrate scope of arynes, good compatibility with functional groups, and high regioselectivity. Representative transformations of the o-haloaminoarenes are described to highlight their utility for rapid access to diversely functionalized a minoarene derivatives.

  DOI：

  10.1021/ol401518c

文献信息

• MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis

  公开号：EP3875452A1

  公开（公告）日：2021-09-08

  Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

  提供的是式(I)的化合物，或其药学上可接受的盐或溶剂： 还提供了包含式(I)化合物的组合物。这些化合物和组合物还可用作药物，例如用于治疗由单酰基甘油脂酶（MAGL）调节的疾病的药物。还提供了利用这些化合物和组合物来抑制单酰基甘油脂酶（MAGL）的用途。
• NEW VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF
  申请人：SHANGHAI SYNCORES TECHNOLOGIES INC. LTD.

  公开号：US20170088530A1

  公开（公告）日：2017-03-30

  The present invention provides a new intermediate II and a method for synthesizing the same. The method comprises: (a) firstly diazotizing a compound of formula I as a raw material, and then halogenating to obtain an intermediate II; and (b) reacting the intermediate II with a compound III to obtain a compound IV, hydrolyzing the obtained compound IV directly without being separated to obtain Vortioxetine represented by compound V. The intermediate II can be used for synthesizing Vortioxetine.

  本发明提供了一种新的中间体II及其合成方法。该方法包括：(a)首先将化合物I作为原料重氮化，然后卤代化以获得中间体II；以及(b)将中间体II与化合物III反应以获得化合物IV，直接水解所得的化合物IV而不进行分离，从而获得化合物V代表的Vortioxetine。中间体II可用于合成Vortioxetine。
• Efficient copper-catalyzed cross-coupling of 1-Boc-piperazine with aryl iodides and its application in the synthesis of trazodone
  作者：Fui-Fong Yong、Yong-Chua Teo、Khee-Ngiap Tan

  DOI：10.1016/j.tetlet.2013.07.104

  日期：2013.9

  convenient and practical strategy is developed for the cross-coupling of N-Boc protected piperazines with aryl iodides using CuBr/1,1′-bi-2-naphthol as the catalyst and K3PO4 as the base. The protocol affords N-arylated piperazine products in moderate to good yields under the optimized conditions. The application of this catalytic system to the synthesis of trazodone is also successfully demonstrated using commercially

  提出了一种方便实用的策略，以CuBr / 1,1'-bi-2-萘酚为催化剂，K 3 PO 4为碱，将N - Boc保护的哌嗪与芳基碘交叉偶联。该协议在优化条件下以中等到良好的产率提供了N-芳基哌嗪产品。使用市场上可买到的底物也成功地证明了该催化体系在合成曲唑酮中的应用。
• BMP INHIBITORS AND METHODS OF USE THEREOF
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20160046633A1

  公开（公告）日：2016-02-18

  The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

  本发明提供了BMP信号通路的小分子抑制剂。这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与BMP信号通路相关的疾病或病症，包括炎症、心血管疾病、血液病、癌症和骨病，以及调节细胞分化和/或增殖。这些化合物还可用于降低ApoB-100或LDL的循环水平，治疗或预防获得性或先天性高胆固醇血症或高脂蛋白血症；与脂质吸收或代谢缺陷相关的疾病、疾病或综合症；或由高脂血症引起的疾病、疾病或综合症。
• BMP inhibitors and methods of use thereof
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US10017516B2

  公开（公告）日：2018-07-10

  The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

  本发明提供了 BMP 信号转导的小分子抑制剂。这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与 BMP 信号转导相关的疾病或病症，包括炎症、心血管疾病、血液病、癌症和骨骼疾病，以及调节细胞分化和/或增殖。这些化合物还可用于降低载脂蛋白B-100或低密度脂蛋白的循环水平，治疗或预防获得性或先天性高胆固醇血症或高脂蛋白血症；与脂质吸收或代谢缺陷相关的疾病、失调或综合症；或由高脂血症引起的疾病、失调或综合症。